French public sceptical of pharma but still has faith in medicines after Mediator scandal
This article was originally published in Scrip
It cannot come as much of a surprise, -in the wake of the Mediator scandal that has gripped France, that the French public believes that the pharmaceutical industry is more concerned about profit than sick patients, according to a study conducted by the French R&D-based industry association, Leem. Nevertheless, reassuringly for industry, patients still trust in their medicines.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.